On Thursday, Following U.S. Stocks were among the “Top Losers”: Memorial Resource Development Corp. (NASDAQ:MRD), Intel Corporation (NASDAQ:INTC), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Memorial Resource Development Corp (NASDAQ:MRD), with shares declined -4.81%, closed at $16.61.
Intel Corporation (NASDAQ:INTC), with shares dropped -4.73%, settled at $30.80.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), with shares dipped -4.72%, and closed at $4.24.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA), plummeted -4.45%, and closed at $2.36.
Latest NEWS regarding these Stocks are depicted underneath:
Memorial Resource Development Corp. (NASDAQ:MRD)
Memorial Resource Development Corp. (MRD), declared its operating and financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter 2014 Results:
Unless otherwise indicated, the operating and financial results talk abouted in this press release only comprise the MRD Segment, which comprises all of MRD’s operations except for Memorial Production Partners LP and its auxiliaries (“MEMP”).
Net production raised 104% year-over-year to 282 MMcfe/d for the fourth quarter 2014 contrast to 139 MMcfe/d for the fourth quarter 2013. Fourth quarter 2014 net production comprised of 225 MMcf/d of natural gas (80%), 6.6 MBbls/d of natural gas liquids (“NGLs”) (14%) and 2.9 MBbls/d of crude oil (6%). In the fourth quarter, about 91% of average daily production was associated with the Terryville Field with the remaining portion attributable to MRD’s East Texas and the Rockies regions. During the fourth quarter 2014, MRD brought online a total of 12 horizontal gross wells, comprising of 11 in the Terryville Field and 1 in East Texas, which was divested in February 2015.
Total proceeds raised 72% to $103.8 million for the fourth quarter 2014 from $60.2 million for the fourth quarter 2013. The raise was primarily due to drilling activity in North Louisiana.
Lease operating expense (“LOE”) for the fourth quarter 2014 was $8.0 million, or $0.31 per Mcfe, contrast to $7.9 million, or $0.62 per Mcfe, for the fourth quarter 2013. The decrease in per unit LOE resulted from raised sales volumes, lower per unit operating cost attributable to pad development and MRD’s continuous efforts to reduce costs.
Production and ad valorem taxes were $3.7 million for the fourth quarter 2014, or $0.14 per Mcfe, contrast to $0.8 million, or $0.06 per Mcfe, for the fourth quarter 2013. Fourth quarter 2014 production and ad valorem taxes raised as compared to fourth quarter 2013 due to higher production and associated proceed.
General and administrative (“G&A”) expense for the fourth quarter 2014 was $12.8 million, or $0.49 per Mcfe, contrast to $16.0 million, or $1.26 per Mcfe, for the fourth quarter 2013. During the fourth quarter 2014, G&A expense comprised of $1.3 million, or $0.05 per Mcfe, of stock-based compensation expense and $0.7 million, or $0.03 per Mcfe, of attainment related costs.
Net interest expense during the fourth quarter 2014 was $5.9 million, counting amortization of deferred financing fees of about $0.7 million. This compares to net interest expense during the fourth quarter 2013 of $11.4 million, counting amortization of deferred financing fees of about $0.8 million. The year-over-year decrease in net interest expense is primarily the result of higher interest rate debt instruments that have since been terminated in addition to $4.5 million of capitalized interest in the fourth quarter 2014.
Capital expenditures totaled $249.5 million in the fourth quarter 2014 and comprised of $96.9 million related to attainments. During the quarter, MRD spent about 97% in the Terryville Field, 2% in East Texas and 1% in the Rockies.
MRD stated Adjusted Net Revenue for the fourth quarter 2014 of $1.8 million contrast to a loss of $1.4 million for the fourth quarter 2013. Adjusted Net Revenue during 2014 was influenced by impairment and exploration expenses related to MRD’s Rockies region.
Memorial Resource Development Corp., an independent natural gas and oil corporation, focuses on the attainment, exploitation, and development of natural gas, natural gas liquids, and oil properties in North Louisiana, in addition to the Rocky Mountains.
Intel Corporation (NASDAQ:INTC)
Intel Corporation (INTC), slashed its proceed outlook for the first quarter by nearly a billion dollars, a sign that demand for personal computers is weakening amid sharp currency fluctuations and other factors. The corporation now anticipates first-quarter proceed to be $12.8 billion, plus or minus $300 million, contrast to the previous expectation of $13.7 billion, plus or minus $500 million.
The change in proceed outlook is a result of weaker than predictable demand for business desktop PCs and lower than predictable inventory levels across the PC supply chain. The corporation believes the changes to demand and inventory patterns are caused by lower than predictable Windows XP* refresh in small and medium business and increasingly challenging macroeconomic and currency conditions, particularly in Europe.
The data center business is meeting expectations.
The corporation is forecasting the mid-point of the gross margin range to remain at 60 percent, plus or minus a couple of percentage points, as lower PC unit volume is offset by higher platform average selling prices. Expectations for R&D and MG&A spending and depreciation in the first quarter remain unchanged.
All other expectations have been withdrawn and will be updated with the corporation’s first-quarter earnings report on April 14.
Business Outlook
Intel’s updated Business Outlook does not comprise the potential influence of any business combinations, asset attainments, divestitures, planned investments and other noteworthy transactions that may be accomplished after March 12.
Status of Business Outlook
Intel’s updated Business Outlook is posted on intc.com and may be reiterated in public or private meetings with investors and others. The updated Business Outlook will be effective through the close of business on March 13 unless earlier updated. Intel’s Quiet Period will start from the close of business on March 13 until publication of the corporation’s first-quarter earnings release, planned for April 14. During the Quiet Period, all of the Business Outlook and other forward-looking statements revealed in the corporation’s news releases and filings with the SEC should be considered as historical, speaking as of preceding to the Quiet Period only and not subject to an update by the corporation.
Intel (INTC) is a world leader in computing innovation. The corporation designs and builds the essential technologies that serve as the foundation for the world’s computing devices. As a leader in corporate responsibility and sustainability, Intel also manufactures the world’s first commercially accessible “conflict-free” microprocessors.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical corporation focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, stated its financial and operational results for the fourth quarter and year ended December 31, 2014.
Recent Corporate Highlights:
Financing
In February 2015, the company declared the closing of an underwritten public offering of ordinary stock which generated net proceeds of about $80.6 million.
Financial Results:
Fourth Quarter Results
Net loss applicable to ordinary stockholders for the three months ended December 31, 2014 was $12.0 million, or $0.14 per diluted share, contrast to a net loss applicable to ordinary stockholders of $6.4 million, or $0.10 per diluted share, for the same period in 2013. There was nominal proceed recognized in each of the fourth quarters of 2014 and 2013. Research and development expenses for the three months ended December 31, 2014 totaled $8.2 million contrast to $3.6 million for the same period in 2013. General and administrative expense for the three months ended December 31, 2014 totaled $3.7 contrast to $2.4 million for the same period in 2013.
Full Year Results
Net loss applicable to ordinary stockholders for the year ended December 31, 2014 was $39.2 million or $0.47 per diluted share, contrast to net loss applicable to ordinary stockholders of $21.1 million, or $0.48 per diluted share, for the same period in 2013. There was nominal proceed recognized during the years ended December 31, 2014 and 2013. Research and development expenses for the year ended December 31, 2014 totaled $27.5 million contrast to $10.5 million for the same period in 2013. General and administrative expenses for the year ended December 31, 2014 totaled $11.3 million contrast to $7.7 million for the same period in 2013.
As of December 31, 2014, our cash, cash equivalents and investments totaled $48.6 million contrast to $35.6 million as of December 31, 2013.
Idera Pharmaceuticals, Inc., a clinical stage biotechnology corporation, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Synta Pharmaceuticals Corp. (SNTA), stated financial results for the fourth quarter and year ended December 31, 2014 and offered an operational update.
2014 Accomplishments and Recent Updates:
Final Results from GALAXY-1 Stated; GALAXY-2 Clinical Trial Remains on Track for Interim Analysis of Overall Survival in 2015. In 2014, Synta declared final results from the global, randomized, multi-center Phase 2b GALAXY-1 study comparing the combination of ganetespib and docetaxel to docetaxel alone for the second-line treatment of advanced non-small cell adenocarcinoma. The final results from this trial, in particular the encouraging overall survival results and tolerability profile in patients whose time from diagnosis of advanced disease is greater than 6 months, support the selection of this population for the ongoing pivotal Phase 3 GALAXY-2 trial.
Five hundred (500) patients have been enrolled in GALAXY-2 to date. The Corporation anticipates, based on current projections and statistical assumptions, that the first interim overall survival (OS) analysis of GALAXY-2 will be conducted in the second half of 2015, and the second interim and final OS analysis will be conducted in 2016. Assuming positive interim results from the ongoing GALAXY-2 trial of ganetespib, and pending regulatory feedback, the Corporation plans to seek regulatory approval of ganetespib in North America and Europe for NSCLC in 2016.
Results from ENCHANT-1 Trial Lead to Selection of Ganetespib for I-SPY 2 Breast Cancer Trial; Enrollment of Ganetespib Arm Ongoing. In 2014, the Corporation declared results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib administered as monotherapy for the treatment of metastatic breast cancer at the 2014 European Breast Cancer Conference (EBCC). The results demonstrated encouraging single-agent activity in both HER2+ and triple-negative disease. The strength of the scientific rationale and evidence of clinical activity in ENCHANT-1 led to the selection of ganetespib for the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). I-SPY 2 is a standing Phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer (Stage 2 or higher) that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neoadjuvant setting. The trial is sponsored by QuantumLeap Healthcare Collaborative, a 501(c)(3) non-profit organization dedicated to accelerating healthcare solutions, and shares a unique partnership with the Foundation for the National Institutes of Health Biomarkers Consortium.
Synta Pharmaceuticals Corp., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, counting cancer and chronic inflammatory diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
